Table 1.
Comparison of Clinicopathologic Variables between Patients with IGBC versus Non-IGBC
| Baseline Variables | Incidental (n = 266, 60%) | Nonincidental (n = 179, 40%) | P Value |
|---|---|---|---|
| Age (years), mean ± SD | 65 ± 12 | 66 ± 11 | 0.63 |
| Male, n (%) | 99 (37) | 57 (32) | 0.29 |
| BMI (kg/m2), mean ± SD | 30 ± 7 | 26 ± 6 | <0.001 |
| Race, n (%) | <0.001 | ||
| White | 194 (79) | 108 (64) | |
| African-American | 27 (11) | 26 (16) | |
| Latino | 15 (6) | 9 (5) | |
| Other | 9 (4) | 25 (15) | |
| Comorbidities*, n (%) | 0.17 | ||
| 0 | 69 (30) | 58 (39) | |
| 1 | 96 (42) | 59 (40) | |
| ≥2 | 63 (28) | 32 (23) | |
| Clinical jaundice, n (%) | 24 (10) | 65 (40) | <0.001 |
| Diagnostic laparoscopy, n (%) | 80 (30) | 71 (40) | 0.05 |
| Distant disease on exploration, n (%) | 45 (17) | 63 (36) | <0.001 |
| Attempted resection, n (%) | 235 (88) | 142 (79) | 0.01 |
| Completed resection, n (%) | 217 (82) | 102 (57) | <0.001 |
| Type of resection, n (%) | <0.001 | ||
| Bile duct only | 9 (5) | 1 (1) | |
| Cholecystectomy only | 23 (10) | 40 (30) | |
| Partial hepatectomy + portal LN | 182 (81) | 69 (51) | |
| Major hepatectomy | 11 (5) | 25 (19) | |
| EBL (mL), mean ± SD | 337 ± 346 | 389 ± 617 | 0.37 |
| Major complicationy† n (%) | 37 (16) | 33 (21) | 0.25 |
| Length of stay (days), mean ± SD | 6.9 ± 5.7 | 6.5 ± 3.0 | 0.64 |
| Final margin status, n (%) | <0.001 | ||
| R0 | 198 (75) | 71 (40) | |
| R1 | 16 (6) | 31 (17) | |
| R2 | 50 (19) | 77 (43) | |
| AJCC T-stage | <0.001 | ||
| Tis/T1a | 9 (4) | 5 (4) | |
| T1b | 14 (6) | 4 (3) | |
| T2 | 116 (50) | 31 (23) | |
| T3 | 80 (35) | 65 (48) | |
| T4 | 11 (5) | 30 (22) | |
| Grade, n (%) | 0.001 | ||
| Low | 24 (12) | 9 (7) | |
| Intermediate | 116 (57) | 60 (43) | |
| High | 62 (31) | 70 (50) | |
| LVI, n (%) | 53 (45) | 65 (64) | 0.01 |
| Perineural invasion, n (%) | 63 (53) | 62 (62) | 0.20 |
| Number of lymph nodes retrieved, mean ± SD | 4.8 ± 5.5 | 4.7 ± 8.0 | 0.82 |
| Any lymph node positive, n (%) | 86 (43) | 65 (60) | 0.009 |
| N1 (regional) node positive, n (%) | 82 (41) | 60 (56) | 0.02 |
| N2 (distant) node sampled, n (%) | 54 (23) | 20 (12) | 0.01 |
| N2 (distant) node positive, n (%) | 14 (19) | 8 (29) | 0.41 |
| AJCC anatomic stage, n (%) | <0.001 | ||
| Stage 0 | 7 (3) | 1 (1) | |
| Stage I | 12 (6) | 6 (4) | |
| Stage II | 51 (23) | 11 (7) | |
| Stage IIIA | 28 (13) | 16 (11) | |
| Stage IIIB | 59 (27) | 30 (20) | |
| Stage IVA | 9 (4) | 18 (12) | |
| Stage IVB | 53 (24) | 68 (45) | |
| Neoadjuvant therapy, n (%) | 8 (3) | 8 (5) | 0.54 |
| Chemotherapy | 8 (3) | 8 (5) | 0.58 |
| Radiation | 1 (0) | 3 (2) | 0.34 |
| Adjuvant therapy, n (%) | 103 (52) | 69 (54) | 0.85 |
| Chemotherapy | 99 (49) | 65 (49) | 1.00 |
| Radiation | 48 (25) | 23 (19) | 0.26 |
| Recurrence, n (%) | 60 (35) | 38 (50) | 0.04 |
| Locoregional only | 11 (18) | 5 (14) | 0.43 |
| Distant | 49 (82) | 30 (86) |
BMI, body mass index; LN, lymph node; EBL, estimated blood loss.
*
Includes hypertension, prior cardiac event, congestive heart failure, diabetes, chronic obstructive pulmonary disease, diabetes, and end-stage renal disease.
† ≥
Clavien-Dindo grade IIIa.